Form 4: Guardant Health Co-CEO Sells 210,000 Shares

Guardant Health Co-Chief Executive Officer AmirAli Talasaz sold 210,000 shares of common stock for over $22.7 million through a pre-arranged 10b5-1 plan.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc. (GH), disposed of 210,000 shares of common stock.
• The transactions occurred on May 20, 2026, and were executed under a Rule 10b5-1(c) pre-arranged trading plan.
• The shares were sold in multiple transactions at weighted average prices ranging from $100.95 to $112.7592 per share.
• The total value of the shares sold is approximately $22,749,000.
• Following these transactions, Talasaz beneficially owns 1,886,504 shares indirectly through the Talasaz and Eskandari 2017 Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, undisclosed negative information, making it an expected part of executive financial planning.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than a reaction to immediate company news, which can mitigate negative market perception of insider selling.

Negatives

• A significant sale of 210,000 shares by a Co-Chief Executive Officer and Director could be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify holdings.
• The total value of shares sold exceeds $22.7 million, representing a substantial reduction in the insider's direct beneficial ownership.

Risks

• Investor sentiment could be negatively impacted by the insider sale, potentially leading to downward pressure on the stock price.
• While executed under a 10b5-1 plan, large insider sales can sometimes be interpreted as a signal of future challenges or a plateau in growth by some market participants.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology and healthcare sectors, particularly for executives with significant equity holdings. While large sales can sometimes raise questions, the pre-arranged nature of 10b5-1 plans typically suggests personal financial planning rather than a reaction to adverse company-specific news, differentiating it from unscheduled sales that might signal more immediate concerns about a company's prospects or valuation compared to peers.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice for executives in publicly traded companies, including those in the biotech sector like Guardant Health, Inc., to manage personal finances and diversify portfolios while adhering to insider trading regulations.
• The volume of shares sold (210,000) is substantial, but the remaining beneficial ownership of 1,886,504 shares indicates continued significant alignment with shareholder interests, which is typical for long-tenured executives in growth-oriented companies.

Related Party Transactions

• The shares are indirectly held by the Talasaz and Eskandari 2017 Family Trust, indicating a transaction involving a trust associated with the reporting person.

Stakeholder Impact

• Shareholders may react to the news of a significant insider sale, potentially leading to short-term volatility in the stock price.
• The sale under a 10b5-1 plan suggests a planned diversification or liquidity event for the Co-CEO, which is a common practice and generally not indicative of a change in company strategy or performance for other stakeholders.

Key Dates

Recommendation

While a significant insider sale occurred, its execution under a pre-arranged 10b5-1 plan suggests it's a planned financial event rather than a reaction to new company-specific information. This reduces the immediate negative signal typically associated with insider selling. Investors should 'hold' and monitor future company performance and other insider activity, as this single event, while notable, does not fundamentally alter the investment thesis for Guardant Health at this time.

Keywords

Guardant Health, GH, Insider Sale, Form 4, AmirAli Talasaz, 10b5-1 Plan, Common Stock, Biotechnology, Healthcare, SEC Filing